High-dose infusional doxorubicin and cyclophosphamide: A feasibility study of tandem high-dose chemotherapy cycles without stem cell support

Clinical Cancer Research

Volumn 3, Issue 12 I, 1997, Pages 2337-2345

  Morgan Jr , Robert J ^a   Doroshow, James H ^a   Venkataraman, Kalyanasundaram ^a   Chang, Karen ^a   Raschko, James ^a   Somlo, George ^a   Leong, Lucille ^a   Tetef, Merry ^a   Shibata, Stephen ^a   Hamasaki, Victor ^a   Margolin, Kim ^a   Forman, Stephen ^a   Akman, Steven ^a   Coluzzi, Paul ^a   Ahn, Chul ^a   Weiss, Lawrence ^a   Gadgil, Uday ^a   Harrison, Jonathan ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE DERIVATIVE; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEART MUSCLE BIOPSY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; FILGRASTIM; GATED BLOOD-POOL IMAGING; HEART; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 2642606983     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hryniuk, W. The importance of dose intensity in the outcome of chemotherapy. In: S. Hellman, V. DeVita, and S. Rosenberg (eds.), Important Advances in Oncology, pp. 121-141. Philadelphia: Lippincott, 1988.
2. Frei, E., III, and Canellos, G. P. Dose: a critical factor in cancer chemotherapy. Am. J. Med., 69: 585-594, 1980.
3. Buckner, C. D., Rudolph, R. H., Fefer, A., Clift, R. A., Epstein, R. B., Funk, D. D., Neiman, P. E., Slighter, S. J., Storb, R., and Thomas, E. D. High-dose cyclophosphamide therapy for malignant disease. Cancer (Phila.), 29: 357-365, 1972.
4. Collins, C., Mortimer, J., and Livingston, R. B. High-dose cyclophosphamide in the treatment of refractory lymphomas and solid tumor malignancies. Cancer (Phila.), 63: 228-232, 1989.
5. Mullins, G. M., Anderson, P. N., and Santos, G. W. High dose cyclophosphamide therapy in solid tumors. Cancer, 36: 1950-1958, 1975.
6. Bonadonna, G., and Valagussa, P. Dose-response effect of adjuvant chemotherapy in breast cancer. N. Engl. J. Med., 304: 10-15, 1981.
7. Tannock, I. F., Boyd, N. F., DeBoer, G., Erlichman, C., Fine, S., Larocque, G., Mayers, C., Perrault, D., and Sutherland, H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J. Clin. Oncol., 6: 1377-1387, 1988.
8. Jones, R. B., Holland, J. F., Bhardwaj, S., Norton, L. Wilfinger, C., and Strashun, A. A phase I-II study of intensive-dose Adriamycin for advanced breast cancer. J. Clin. Oncol., 5: 172-177, 1987.
9. Wheeler, R. H., Ensminger, W. D., Thrall, J. H., and Anderson, J. L. High-dose doxorubicin: an exploration of the dose-response curve in human neoplasia. Cancer Treat. Rep., 66: 493-498, 1982.
10. Billingham, M. E., and Bristow, M. R. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat. Symp., 3: 71-76, 1984.
11. Billingham, M. E., Mason, J. W., Bristow, M. R., and Daniels, J. R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep., 62: 865-872, 1978.
12. Anderson, J. L., and Marshall, H. W. The femoral venous approach to endomyocardial biopsy: comparison with internal jugular and transarterial approaches. Am. J. Cardiol., 53: 833-837, 1984.
13. French, W., Siegel, R. J., Cohen, A. H., and Laks, M. M. Yield of endomyocardial biopsy in patients with biventricular failure: comparison of patients with normal vs. reduced left ventricular ejection fraction. Chest, 90: 181-184, 1986.
14. Sheibani, K., and Battifora, H. Signet-ring cell melanoma: a rare morphologic variant of malignant melanoma. Am. J. Surg. Pathol., 12: 28-34, 1988.
15. Margolin, K. A., Doroshow, J. H., Akman, S. A., Leong, L. A., Morgan, R. J., Raschko, J. W., Somlo, G., and Blevins, C. Effective initial therapy of advanced breast cancer with fluorouracil and high-dose, continuous infusion calcium leucovorin. J. Clin. Oncol., 10: 1278-1283, 1992.
16. Zeger, S., and Liang, K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics, 42: 121-130, 1986.
17. Dunn, O., and Clark, V. Applied Statistics: Analysis of Variance and Regression. New York: Wiley, 1987.
18. Hryniuk, W. M. The importance of dose intensity in the outcome of chemotherapy. In: S. Hellman, V. DeVita, and S. Rosenberg (eds.), Important Advances in Oncology, pp. 121-141. Philadelphia: Lippincott, 1988.
19. Henderson, I. C., Hayes, D. F., and Gelman, R. Dose-response in the treatment of breast cancer: a critical review. J. Clin. Oncol., 6: 1501-1515, 1988.
20. Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., Ballow, A. C., Frei, E., III, and Henderson, I. C. Dose and dose intensity of adjuvant chemotherapy for stage II node-positive breast carcinoma. N. Engl. J. Med., 330: 1253-1259, 1994.
21. Dimitrov, N., Anderson, S., Fisher, B., Redmond C., Wickerham, D. L., Pugh, R., Spurr, C., Goodnight, J., Abramson, N., and Wolter, J. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: findings from NSABP B-22. Proc. Am. Soc. Clin. Oncol., 13: 64, 1994.
22. Peters, W. P., Ross, M., Vredenbrugh, J. J., Meisenberg, B., Marks, L. B., Winer, E., Kurtzberg, J., Bast, R., Jr., Jones, R., Shpall, E., Wu, K., Rosner, G., Gilbert, C., Mathias, B., Coniglio, D., Petros, W., Henderson, I. C., Norton, L., Weiss, R. B., Budman, D., and Hurd, D. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol., 11: 1132-1143, 1993.
23. Doroshow, J. H. Doxorubicin-induced cardiac toxicity. N. Engl. J. Med., 324: 843-845, 1991.
24. Hertenstein, B., Stefanic, M., Schmeiser, T., Scholz, M., Goller, V., Clausen, M., Bunjes, D., Wiesneth, M., Novotny, J., Kochs, M., Adam, W. E., Heimpel, H., and Arnold, R. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J. Clin. Oncol., 12: 998-1004, 1994.
25. Basser, R. L., To, L. B., Begley, C. G., Juttner, C. A., Maher, D. W., Szer, J., Cebon, J., Collins, J. P., Russell, I., Olver, I., Gill, P. G., Fox, R. M., Sheridan, W. P., and Green, M. D. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. Clin. Cancer Res., 1: 715-721, 1995.
26. Braverman, A. C., Antin, J. H., Plappert, M. T., Cook, E. F., and Lee, R. T. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J. Clin. Oncol., 9: 1215-1223, 1991.
27. Gottdiener, J. S., Appelbaum, F. R., Ferrans, V. J., Deisseroth, A., and Ziegler, J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch. Intern. Med., 141: 758-763, 1981
28. Legha, S. S., Benjamin, R. S., Mackay, B., Ewer, M., Wallace, S., Valdivieso, M., Rasmussen, S. L., Blumenschein, G. R., and Freireich, E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Int. Med., 96: 133-139, 1982.
29. Brugger, W., Bross, K. J., Glatt, M., Weber, F., Mertelsmann, R., and Kanz, L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood, 83: 636-640, 1994.
30. Bronchud, M. H., Howell, A., Crowther, D. Hopwood P., Souza, L., and Dexter, T. M. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br. J. Cancer, 60: 121-125, 1989.
31. Neidhart, J., Mangalik, A., Kohler, W., Stidley, C. Saiki, J., Duncan, P., Souza, L., and Downing, M. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J. Clin. Oncol., 7: 1685-1692, 1989.
32. Somlo, G., Doroshow, J. H., Forman, S. J., Leong, L. A., Margolin, K. A., Morgan, R., Jr., Raschko, J. W., Akman, S. A., Ahn, C., and Sniecinski, I. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer (Phila.), 73: 125-134, 1994.
33. Somlo, G., Doroshow, J. H., Forman, S. J., Leong, L. A., Margolin, K. A., Morgan, R., Jr., Raschko, J. W., Akman, S. A., Ahn, C., Nagasawa, S., Harrison, J., Stein, A., Smith, E., Sniecinski, I., and Schmidt, G. M. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer (Phila.), 73: 1678-1685, 1994.